Eber O, Langsteger W
Krankenhaus der Barmherzigen Brüder, Graz-Eggenberg.
Acta Med Austriaca. 1994;21(1):1-7.
AITD (autoimmune thyroid disease) comprise atrophic thyroiditis (AT), hypertrophic Hashimoto's thyroiditis (HT), and immunogenic hyperthyroidism (Graves' disease, GD). Combinations with other types of autoimmune disorders frequently occur and are called polyglandular autoimmune syndrome. Familial disposition may be documented by genetic markers: GD and AT are associated with HLA-B8 and DR3 respectively, while HT associates with DR5. Pathogenesis of the fore-mentioned 3 AITD may be explained on the one hand by an immunological balance and on the other hand by a predominance of either stimulating or destructive/blocking immune processes. In diagnosing AITD the determination of antibodies against thyroglobulin or thyroidal peroxidase have been in use for quite some times. Antibodies directed against TSH receptors (TRAb) are determined by means of a radioligand assay which will not distinguish between stimulating or blocking antibodies, so that clinical symptoms and thyroid function parameters are essential in evaluating hyper- oder hypothyroid function. TRAb are transferred via the placenta and should therefore be determined in patients with AITD within the 3rd trimester of pregnancy. The prevalence of AITD is far higher in iodine rich countries and is 4 times more frequent in women, with a general age peak between the 5th and 6th decade. The rare AT mostly presents as primary myxoedema and is discovered less frequently during the exploration of an unclear hypercholesterolemia. In HT we differentiate between the chronic fibrous and the juvenile oxiphilic variant. In the former fibrosis is predominant with plasmacellular infiltration producing extremely high titers of antibodies enabling diagnosis without fine needle biopsy (FNB). In the latter, the oxiphilic variant, titers of antibodies are mostly low or even missing so that a reliable diagnosis will require a FNB. However, two thirds of adolescent goitres are caused by HT.
自身免疫性甲状腺疾病(AITD)包括萎缩性甲状腺炎(AT)、肥厚性桥本甲状腺炎(HT)和免疫性甲状腺功能亢进症(格雷夫斯病,GD)。AITD常与其他类型的自身免疫性疾病合并出现,被称为多腺体自身免疫综合征。家族倾向可通过基因标记证实:GD和AT分别与HLA - B8和DR3相关,而HT与DR5相关。上述3种AITD的发病机制一方面可通过免疫平衡来解释,另一方面可通过刺激或破坏/阻断免疫过程的占优来解释。在诊断AITD时,检测抗甲状腺球蛋白或甲状腺过氧化物酶抗体已应用了相当长的时间。针对促甲状腺激素受体(TRAb)的抗体通过放射性配体分析来测定,该方法无法区分刺激抗体或阻断抗体,因此临床症状和甲状腺功能参数对于评估甲状腺功能亢进或减退至关重要。TRAb可通过胎盘传递,因此对于患有AITD的孕妇,应在妊娠晚期测定TRAb。AITD在碘丰富的国家患病率要高得多,女性患病率是男性的4倍,发病年龄高峰一般在50至60岁之间。罕见的AT大多表现为原发性黏液水肿,在不明原因的高胆固醇血症检查中较少被发现。对于HT,我们可区分慢性纤维性和青少年嗜酸性变体。在前者中,纤维化为主,伴有浆细胞浸润,产生极高滴度的抗体,无需细针穿刺活检(FNB)即可诊断。在后者,即嗜酸性变体中,抗体滴度大多较低甚至缺失,因此可靠的诊断需要FNB。然而,青少年甲状腺肿的三分之二是由HT引起的。